April, 2019 | PharmaShots

Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases

April 30, 2019June 18, 2019Tuba Khan

Shots: The Atherosclerosis Risk in Communities (ARIC) study results involves assessing of high-sensitive troponin-I blood test in 8,121 candidates with no known cardiovascular [Read More...]

AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

April 30, 2019June 13, 2019Tuba Khan

Shots: AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) [Read More...]

Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

April 30, 2019June 13, 2019Tuba Khan

Shots: Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of [Read More...]

ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

April 30, 2019June 13, 2019Tuba Khan

Shots: The submission is based on P-III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies results assessing Cabotegravir [Read More...]

Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

April 30, 2019June 13, 2019Tuba Khan

Shots: EirGenix to receive upfront, milestones with profit sharing on sales and will be responsible for the development & manufacturing of proposed biosimilar [Read More...]

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

April 29, 2019June 13, 2019Shiwani Sharma

Shots: The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD, IV, q4days) in 270 patients previously treated with severe [Read More...]